Active Kidney Cancer Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

Why Consider a Kidney Cancer Clinical Trial?

• Find Trials That Fit — Browse recruiting Kidney Cancer trials pulled directly from ClinicalTrials.gov — updated continuously so you always see real, active studies.
• No Medical Jargon — Eligibility criteria are rewritten into plain yes-or-no questions. It's always okay to answer "not sure" — your doctor can help fill in the rest.
• See How Well You Match — Get a clear picture of how closely a trial fits your situation, so you know which ones are worth bringing to your oncologist.
• Ready for Your Appointment — Generate a printable or emailable summary for your next visit. A caregiver can send it to your doctor ahead of time.

How It Works

1. Share a Few Details — Enter your Kidney Cancer type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Kidney Cancer Clinical Trial FAQ

What kidney cancer treatments are currently being studied in clinical trials?

Active trials are testing novel immunotherapy combinations (nivolumab + ipilimumab variants, PD-1 plus LAG-3 inhibitors), TKI plus immunotherapy combinations (cabozantinib, lenvatinib, axitinib combinations), HIF-2α inhibitors (belzutifan and next-generation agents, especially for VHL-mutated disease), and antibody-drug conjugates targeting kidney cancer antigens.

Are there kidney cancer trials for non-clear cell histology?

Yes, though options are more limited. Non-clear cell renal cell carcinoma (papillary, chromophobe, collecting duct, medullary) has been underrepresented in trials historically. Several trials now specifically enroll non-clear cell subtypes, or include them in basket trials. MET inhibitors are particularly promising for papillary RCC.

Do I need to have had prior treatment to join a kidney cancer trial?

No. First-line trials enroll patients who have not yet received systemic treatment. Second-line and later-line trials enroll patients whose cancer has progressed on prior therapy. Trialify lets you specify your treatment history so you only see trials that match your current situation.

What is VHL disease, and does it affect kidney cancer trial eligibility?

VHL (von Hippel-Lindau) disease is a hereditary condition associated with clear cell RCC. HIF-2α inhibitors like belzutifan are FDA-approved for VHL-related kidney cancer and are being tested in sporadic (non-hereditary) clear cell RCC trials. Genetic testing for VHL mutations can open access to specific trial pathways.

Can I join a kidney cancer trial if my cancer has spread to the bone?

Bone metastases are common in advanced kidney cancer and do not automatically exclude you from trials. Most systemic therapy trials enroll patients with bone metastases. Some trials may require stable bone disease (no new lesions in a recent scan) or specify limits on the number of metastatic sites. Trialify's eligibility questions will flag these criteria.

Explore Other Cancer Trial Guides

• Bladder Cancer — Bladder cancer trials are evaluating checkpoint immunotherapy, enfortumab vedotin-based combinations, and FGFR inhibitors for both non-muscle-invasive and muscle-invasive disease.
• Lung Cancer — Lung cancer is the leading cause of cancer-related death worldwide. Recruiting clinical trials are testing new immunotherapies, targeted therapies, and combination regimens for NSCLC and SCLC patients.
• Melanoma — Melanoma trials are studying next-generation checkpoint inhibitors, tumor-infiltrating lymphocyte (TIL) therapy, and BRAF/MEK targeted combinations — including adjuvant options for resected disease.
• Liver Cancer — Liver cancer trials are studying checkpoint inhibitor combinations, locoregional treatments (TACE, ablation), and novel targeted agents for hepatocellular carcinoma across all disease stages.